The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.
An article from
Dive Brief
The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.
Published Aug. 14, 2026
Entrance sign of the Bristol Myers Squibb office in Summit, N.J., on Aug. 13, 2023.
Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma
FDA approves Bristol Myers’ multiple myeloma successor
FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
FDA Approves First CELMoD Drug for Multiple Myeloma
It's BMS vs. Celgene investors once more after US appeals court revives lawsuit
SFDA becomes first regulatory authority globally to approve registration of 'ZENBEXUS' to treat multiple myeloma in adults
Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therapy approval.
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab…
The FDA has granted accelerated approval to the first cereblon E3 ligase modulation therapy for patients with multiple…
Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its…
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of…
FDA approved Bristol Myers Squibb's iberdomide (Zenbexus) for relapsed/refractory multiple myeloma at $29,500/cycle, used with…
